Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

Nature Medicine has published an Author Correction to the phase 1 trial of cevostamab, an FcRH5×CD3 bispecific antibody, in relapsed or refractory multiple myeloma. The left x-axis labels of both panels in Extended Data Fig. 3b are changed from "No 1q gain or amp" to "1q normal". The HTML and PDF versions have been updated.